7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
03. September 2024 14:02 ET
|
7 Hills Pharma
7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03. Juni 2024 12:57 ET
|
7 Hills Pharma
Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
03. August 2023 07:05 ET
|
Morphic Therapeutic
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater...
Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree
28. September 2022 12:00 ET
|
Morphic Therapeutic
Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic...
7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
09. November 2020 05:30 ET
|
7 Hills Pharma
HOUSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
10. August 2020 07:00 ET
|
Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
18. Juni 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic to Present at the Jefferies Virtual Healthcare Conference
27. Mai 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
06. Mai 2020 16:05 ET
|
Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
29. April 2020 16:15 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...